News|Articles|November 18, 2026

Dazodalibep Shows Phase 3 Benefit in Sjögren Disease

Author(s)Habiba Atta
Fact checked by: Maggie L. Shaw
Listen
0:00 / 0:00

Key Takeaways

  • Patient-reported dryness improved with q4w dosing, with placebo-adjusted ESSPRI dryness −1.17 and DASPRI dryness −0.93 at week 48 (adjusted P<.001 for both).
  • Treatment effect emerged by week 4 and persisted through week 48, supporting sustained modulation of CD40L-mediated immune signaling in systemic Sjögren disease.
SHOW MORE

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

Dazodalibep, an investigational CD40L antagonist, significantly reduced systemic disease activity in patients with Sjögren disease and moderate to severe systemic disease activity, according to full results from the phase 3 OASIZ-301 trial (NCT06104124) presented as a late-breaking abstract at ACR Convergence 2026.1 Sjögren disease is the second most common autoimmune rheumatic disease, yet no disease-modifying therapy is FDA approved for it.2 Beyond dryness, fatigue, and pain, many patients have systemic organ involvement.1

Dazodalibep Reduced Systemic Disease Activity in Phase 3 OASIZ-301 Trial

The randomized, double-blind, placebo-controlled trial enrolled 648 patients with moderate to severe systemic disease, defined as a European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) score of at least 5. The mean baseline ESSDAI score was 10.2. Patients received dazodalibep 1500 mg every 4 weeks, dazodalibep 3000 mg every 12 weeks, or placebo. At week 48, the every-4-weeks regimen (n = 217) reduced ESSDAI scores by a least-squares mean of 5.6 points from baseline vs 3.8 points with placebo (adjusted P < .001). The every-12-weeks regimen (n = 217) reduced scores by 5.2 points, a 1.4-point difference vs placebo (adjusted P = .010). A treatment effect appeared as early as week 4 and was sustained through week 48.

“These phase 3 results support dazodalibep's potential as a first-in-class treatment for Sjögren's disease and strengthen the clinical rationale for targeting CD40L-mediated immune signaling in these patients,” said Jay Bradner, MD, executive vice president of research and development, artificial intelligence and data Amgen.

Does Dazodalibep Improve Dryness in Sjögren Disease?

The every-4-weeks regimen also significantly improved patient-reported dryness at week 48. Placebo-adjusted least-squares mean differences were −1.17 points on the dryness domain of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and −0.93 points on the dryness domain of the Diary for Assessing Sjögren's Patient Reported Index (DASPRI) (adjusted P < .001 for both). Dryness results for the every-12-weeks regimen were not reported.

Total ESSPRI and DASPRI scores favored dazodalibep over placebo across 48 weeks. Amgen reported mean improvement in total ESSPRI of more than 1.5 points with both regimens, which it called consistent with clinically meaningful improvement; the release did not specify whether this figure was placebo-adjusted. The results for other significant secondary end points, including tender and swollen joints and fatigue, were not included in the announcement.

“In OASIZ-301, both dosing regimens reduced systemic disease activity compared with placebo, and the every-4-weeks regimen also improved patient-reported dryness,” said lead investigator Ghaith Noaiseh, MD, associate professor of medicine at the University of Kansas Medical Center.

Safety and Next Steps for Dazodalibep in Sjögren Disease

The most common adverse events (AEs) occurring in at least 5% of patients and more often with dazodalibep than placebo were nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions, which were generally mild to moderate. Serious AEs and discontinuations due to AEs were balanced across the 3 groups. There was no imbalance in thromboembolic events or opportunistic infections, and malignancy rates were low and comparable.

Dazodalibep is a CD40L antagonist fusion protein designed to disrupt CD40L-mediated immune activation. Amgen is also testing it in OASIZ-303 (NCT06245408), a phase 3 trial in patients with high symptom burden but low systemic disease activity, and in OASIZ-304 (NCT06747949), an open-label extension study evaluating long-term safety and tolerability in eligible participants from both trials.

References

  1. Amgen announces positive phase 3 results for dazodalibep in Sjögren's disease. News release. Amgen. November 11, 2026. Accessed November 17, 2026. https://wwwext.amgen.com/newsroom/press-releases/2026/11/amgen-announces-positive-phase-3-results-for-dazodalibep-in-sjgrens-disease
  2. Joszt L. Pipeline advances in Sjögren disease bring targeted therapies closer. AJMC®. October 2, 2026. Accessed November 17, 2026. https://www.ajmc.com/view/pipeline-advances-in-sj-gren-disease-bring-targeted-therapies-closer

Related to this article